Cyclerion Therapeutics Inc. Common Stock (CYCN)

FairStock Score: 28/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable businesses with honest financials and a margin of safety, and Cyclerion fails most of my tests. It is a clinical-stage biopharmaceutical company developing sGC stimulators: Olinciguat is in Phase 2 for cardiovascular disease and Praliciguat is for rare kidney disease. It reports only one employee, so it is essentially a virtual shell around clinical programs. In the 2025-Q4 quarter, it reported revenue of $1.0M and net income of -$799,000. Trailing free cash flow is -$4.5M, and the FairStock FCF yield is -35.2% against a $12.8M market cap. Revenue growth is -43.24% and profit growth is -250.75%. The balance-sheet and quality metrics are alarming: Altman Z-score -51.88, Piotroski F-score 2/9, ROE -98.22%, ROCE -52.33%. There is no meaningful moat because there is no approved product, no scale, and no pricing power; value depends on clinical trial outcomes. At the 2026-09-08 close of $23.94, the FairStock P/B is 2.86 and the P/E is negative. The stock trades far above its 52-week low of $1.03 but below its high of $36.33, with beta 1.75. FairStock score is 28/100. The Lynch category is none because only 0 years of filed annual results are available and three are needed. This is not a Graham bargain; it is a lottery ticket on science. I would need proof of cash runway and trial success before ascribing value.

In plain English: Cyclerion Therapeutics is a tiny biotech company working on experimental medicines for serious heart, kidney, and nervous-system diseases. The business looks weak today: it is losing money, revenue is falling, and it burns cash. At the recent $23.94 close, the price does not look cheap against its current sales, losses, and book value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-09-08 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer